Loading clinical trials...

Is Neutrophil to Lymphocyte Ratio a Prognostic Factor of Sepsis in Newborns With Operated Neural Tube Defects? | Clinical Trials | Clareo Health

Back to search

COMPLETED

Is Neutrophil to Lymphocyte Ratio a Prognostic Factor of Sepsis in Newborns With Operated Neural Tube Defects?

NCT04135274•Tepecik Training and Research Hospital

View on ClinicalTrials.gov

Summary

We aimed to investigate whether Neutrophil Lymphocyte Ratio is a Prognostic Factor of Sepsis in Newborns with operated Neural Tube Defects?

Eligibility

Age

0 - 0 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•\<28 days diagnosed with with neural Tüpe Defects To be operated

Exclusion Criteria

•\>28 days

Key Dates

Start Date

January 1, 2015

Primary Completion Date

December 30, 2018

Completion Date

December 30, 2018

Last Updated

October 22, 2019

Enrollment

ACTUAL participants

Conditions

Neural Tube DefectsNewborn Sepsis

Interventions

Neutrophil to lymphocyte ratio

DIAGNOSTIC_TEST

Patch vs. No Patch Fetoscopic Meningomyelocele Repair Study

NCT03794011

Neural Tube Defects

View study

COMPLETEDNA

Minimally Invasive Fetoscopic Regenerative Repair of Spina Bifida - A Pilot Study

NCT03936322

Spina BifidaMyelomeningocele+1 more

View study

TERMINATED

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 22, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions